UCB, Roche to develop antibodies for Alzheimer's disease Biopharmaceutical firm UCB has signed a deal to provide Roche and Genentech with an exclusive, worldwide license to its UCB0107 antitau antibody treatment for people living with Alzheimer's disease.Read More
Omega Therapeutics advances epigenomic programming platform Omega Therapeutics has received $85 million in financing to support clinical trials of its epigenomic controllers for programs in oncology, inflammation, autoimmune, metabolic, and rare genetic diseases.Read More
Avacta, Daewoong partner on COVID-19 therapy Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19 patients.Read More
ASU, World Economic Forum launch business survey for COVID-19 Arizona State University (ASU) and the World Economic Forum have launched COVID-19 Diagnostics Commons, a project that will survey businesses and share knowledge about how to safely and effectively bring employees back to work.Read More
Soligenix advances COVID-19 vaccine Biopharmaceutical firm Soligenix said that preclinical immunogenicity studies of its CiVax heat stable subunit COVID-19 vaccine candidate demonstrated that both broad-spectrum antibody immunity and cell-mediated rapid onset immunity are possible using the CoVaccine HT adjuvant.Read More